Aug 2026· Cell Reports· Vol 45, pp. 117884 - 117884· 0 citations· 85 references
Medicine
TL;DR
This study analyzes the surfaceomes and global proteomes of 22 unique OS patient-derived xenografts (PDXs) using mass spectrometry to identify surface proteins for potential immunotherapeutic targeting and identifies several poorly characterized targets, including ROR2 and TMEM119.
Abstract
SUMMARY Osteosarcoma (OS) is the most common human primary bone cancer, primarily affecting children and young adults. While the survival rate of patients diagnosed with localized OS is ~65%, this decreases to ~20% for patients with metastatic disease, and recurrent disease remains largely incurable. Therefore, identifying new therapeutic strategies is urgently needed for metastatic and refractory OS. This study analyzes the surfaceomes and global proteomes of 22 unique OS patient-derived xenografts (PDXs) using mass spectrometry to identify surface proteins for potential immunotherapeutic targeting. Both methods identify known OS-associated surface candidates including LRRC15, MMP14, MRC2, and CADM1, and several poorly characterized targets, including ROR2 and TMEM119. Both ROR2 and TMEM119 display robust expression in OS tissues but only limited or no expression in normal pediatric tissues, and loss of both targets reduces the migration of OS cells. These data provide a resource of surface proteins as potential immunotherapeutic targets in OS.
Background & Aims Biliary tract cancers (BTCs) are a rare set of genetically heterogenous and aggressive malignancies associated with delayed presentation and poor prognosis. Thus, there is an unmet clinical need for the development of novel therapeutic strategies. Identification of uniquely expressed cell-surface, tum...
Lorraine Nuniz, Julia H. Pham, Juliette Jacques et al.· bioRxiv· 0 citations
BACKGROUND
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The overall survival has not improved significantly over the last decades because no major therapeutic breakthroughs have been achieved for over 15 years.
METHODS
We analyzed a genome-wide loss-of-function screening database to ident...
N. Matsumoto, K. Tajima, Fumiyuki Takahashi et al.· Respiratory Investigation· 2 citations
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor treatment options, emphasizing the need for novel therapeutic targets. Hub proteins have high connectivity (i.e., many interaction partners) and often act as central biological regulators. Here, we aimed to identify hub proteins with potential...
Foram Vyas, Virginie Defamie, Kelvin Yeung et al.· Cancer Research· 0 citations
Peritoneal metastasis confers a dismal prognosis in colorectal cancer (CRC-PM), with median survival rarely exceeding 20 months. Here we employed multi-omic profiling to identify actionable drivers of CRC-PM. We performed whole-exome sequencing (WES) and label-free quantitative proteomics on 13 and 7 matched primary-pe...
Zhi-Wei Zhang, Zhi-Yuan Gong, Akao Zhu et al.· International Journal of Mol...· 0 citations
Triple-negative breast cancer (TNBC) is characterized by high malignancy, poor prognosis and a lack of specific therapeutic targets. Obesity acts as a major risk factor facilitating TNBC progression, while the molecular features underlying their correlation remain poorly systematically characterized. In this study, w...
Simple Summary TFAP2E, encoding the AP-2ε transcription factor, remains poorly characterized in cancer despite the established regulatory importance of the AP-2 family. This study first evaluated tumor–normal expression differences across a pan-cancer spectrum to prioritize ovarian serous carcinoma for investigation, a...
D. Kołat, Julia Gałęziewska, Paulina Buczek et al.· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.